Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drug shows promise for heart health beyond sugar control

NCT ID NCT03498001

First seen Feb 04, 2026 · Last updated Jun 19, 2026 · Updated 20 times

Summary

This study looked at how GLP-1 agonist drugs (like liraglutide) affect fat buildup in the heart of people with type 2 diabetes. 42 adults over 50 with diabetes and at least one heart risk factor took part. The goal was to see if these drugs reduce heart fat, which may help protect the heart.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE II DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, 21000, France

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.